Coulter Briefs
Briefer items of interest to the UVA-Coulter community
Co-Inventor of One of the Most Prescribed HIV Drugs Joins HemoShear
October 23, 2019HemoShear Therapeutics Appoints Brian A. Johns, PhD, Chief Scientific Officer
HemoShear Therapeutics, LLC, a privately held biotechnology company focused on discovering and developing drugs for metabolic disorders, has appointed Brian A. Johns, PhD, as Chief Scientific Officer. Dr. Johns joins the company following a prolific 20-year career with GSK, where he co-invented Tivicay® (dolutegravir), one of the most widely prescribed antivirals for HIV in the world. Dr. Johns also discovered an investigational drug called cabotegravir, the first long-acting HIV treatment, which is under FDA review.
Coulter Director is Committed to Training the Next Generation of Inventors
August 08, 2019Bio-Med TechGirls is the brainchild of UVA Coulter Program Director David Chen and K-12 STEM educator Kim Wilkens. Now in its sixth year, the program brings teen girls to UVA Engineering and the School of Medicine for a week of behind-the-scenes lab tours, guest speakers, hands-on computer science learning and a design challenge to create technology to assist disabled children.
Teen girls challenged with creating technology for disabled children (CBS 19 News Story)
FDA grants de novo for the HemoSonics’ Quantra® QPlus® System
April 24, 2019This Revolutionary Diagnostic Provides Unique Information for Assessing Coagulation at the Point of Care; Now Commercially Available in US
Speechless: You Don’t Need to be a Singer to Lose Your Voice
April 23, 2019With help from Coulter, James Daniero (profiled in the story) and Don Griffin are validating a new injectible filler for reconstructing the larynx.
Read More: Speechless: You Don’t Need to be a Singer to Lose Your Voice
2019 Call for Proposals
February 19, 2019Application Deadline is Thursday April 25, 2019. 2019 Coulter Request for Proposals (PDF)
PROGRAM: The Wallace H. Coulter Foundation Translational Partners Program supports collaborative translational research projects in the field to Biomedical Engineering. The goal of this program is to provide funding to develop translational research projects that address unmet clinical needs and lead to improvements in health care. Examples of desirable outcomes include improved diagnosis and treatment of disease through new medical devices, new biomarkers, new therapeutic targets, and/or new clinical adoption of existing tools. Although not required, most projects will result in commercial partnerships, new intellectual property and startup companies. Both short-term and long-term/high-risk projects are eligible. On average, the Program supports 6-8 projects and invests over $800,000 of project funds every year.
ELIGIBILITY: Permanent, full-time, tenure-track faculty in the professorial ranks (assistant, associate, full).